Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, President and CEO, will participate in the Piper Sandler 33rd Virtual Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, President and CEO, will participate in the Piper Sandler 33rd Virtual Annual Healthcare Conference. The conference is scheduled from November 30 to December 2, 2021. A pre-recorded presentation will be available on-demand starting November 22, 2021, at 10:00 am ET, accessible via the Investors section of Vor's website. Vor Biopharma focuses on engineering hematopoietic stem cells to improve treatments for blood cancers.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -8.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.
Piper Sandler 33rd Virtual Annual Healthcare Conference
Date: Tuesday, November 30 through Thursday, December 2, 2021
Vor’s pre-recorded presentation will be available on-demand from Piper Sandler beginning on Monday, November 22nd at 10:00 am ET and can also be accessed via the Investors section of the Company's website at www.vorbio.com.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Vice President, Corporate Communications, Vor
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.